C-DWDMNAD+ supplementation, cellular aging, biological age
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Create selective senolytic agents suitable for anti-aging applications by targeting senescent cells.
Patent-covered compositions including senolytic agents; the record references magnolol and formulations for oral, topical, or transdermal administration.
US patent application published and listed as pending.
Mitigate effects of aging by enhancing cellular resistance to DNA damage, oxidative stress, and mitochondrial stress.
Patent-covered compositions for oral, topical, or transdermal application intended to protect cells from oxidative and mitochondrial stress.
PCT patent publication listed as ceased.
Increase NAD+ and support healthy aging, cellular health, energy, vitality, performance, recovery, inflammation, sleep quality, and brain fog.
Dietary NAD+ boosting supplement developed using a systems-based approach targeting multiple points in the NAD+ salvage pathway; evaluated in a double-blind, randomised, crossover human trial.
Published human trial evidence showing Nuchido TIME+ increased whole-blood NAD+ and affected biomarkers associated with healthier aging.
Increased NAD+ concentration in whole blood; associated with increased SIRT1 and NAMPT in peripheral blood mononucleocytes, lower pro-inflammatory cytokines including IL2, reduced glycated serum protein, and IgG glycosylation shifted toward a younger biological age.
Develop more reliable interventions to restore NAD+ by addressing biological complexity behind age-related NAD+ decline.
Research program proposing multi-node targeting of the NAD+ interactome rather than single-target NAD+ precursor supplementation.
Published review and rationale for a systems approach to NAD+ restoration.
The publication argues that variability in NAD+ supplement efficacy may result from single-target approaches and that targeting multiple key nodes in the NAD+ interactome is likely to be more efficacious and reliable.